FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2385703614> ?p ?o ?g. }

• W2385703614 abstract "Abstract Background Our objective was to evaluate the efficacy (clinical and biomarker) and safety of intravenous bapineuzumab in patients with mild to moderate Alzheimer’s disease (AD). Methods Two of four phase 3, multicenter, randomized, double-blind, placebo-controlled, 18-month trials were conducted globally: one in apolipoprotein E ε4 carriers and another in noncarriers. Patients received bapineuzumab 0.5 mg/kg (both trials) or 1.0 mg/kg (noncarrier trial) or placebo every 13 weeks. Coprimary endpoints were change from baseline to week 78 on the 11-item Alzheimer’s Disease Assessment Scale–Cognitive subscale and the Disability Assessment for Dementia. Results A total of 683 and 329 patients completed the current carrier and noncarrier trials, respectively, which were terminated prematurely owing to lack of efficacy in the two other phase 3 trials of bapineuzumab in AD. The current trials showed no significant difference between bapineuzumab and placebo for the coprimary endpoints and no effect of bapineuzumab on amyloid load or cerebrospinal fluid phosphorylated tau. (Both measures were stable over time in the placebo group.) Amyloid-related imaging abnormalities with edema or effusion were confirmed as the most notable adverse event. Conclusions These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD. Some differences in the biomarker results were seen compared with the other phase 3 bapineuzumab trials. No unexpected adverse events were observed. Trial registration Noncarriers (3000) ClinicalTrials.gov identifier NCT00667810 ; registered 24 Apr 2008. Carriers (3001) ClinicalTrials.gov identifier NCT00676143 ; registered 2 May 2008." @default.
• W2385703614 created "2016-06-24" @default.
• W2385703614 creator A5009252002 @default.
• W2385703614 creator A5012191847 @default.
• W2385703614 creator A5016385021 @default.
• W2385703614 creator A5017541810 @default.
• W2385703614 creator A5020136275 @default.
• W2385703614 creator A5020866326 @default.
• W2385703614 creator A5025513316 @default.
• W2385703614 creator A5025870220 @default.
• W2385703614 creator A5033389610 @default.
• W2385703614 creator A5043338100 @default.
• W2385703614 creator A5049484291 @default.
• W2385703614 creator A5050897246 @default.
• W2385703614 creator A5052077345 @default.
• W2385703614 creator A5061039783 @default.
• W2385703614 creator A5071341444 @default.
• W2385703614 creator A5071619668 @default.
• W2385703614 creator A5076601074 @default.
• W2385703614 creator A5083343966 @default.
• W2385703614 creator A5086549440 @default.
• W2385703614 creator A5087508465 @default.
• W2385703614 creator A5087888043 @default.
• W2385703614 creator A5091783652 @default.
• W2385703614 date "2016-05-12" @default.
• W2385703614 modified "2023-10-18" @default.
• W2385703614 title "Bapineuzumab for mild to moderate Alzheimer’s disease in two global, randomized, phase 3 trials" @default.
• W2385703614 cites W1824074994 @default.
• W2385703614 cites W1980564700 @default.
• W2385703614 cites W1992474532 @default.
• W2385703614 cites W2004535959 @default.
• W2385703614 cites W2015484447 @default.
• W2385703614 cites W2053936304 @default.
• W2385703614 cites W2063808031 @default.
• W2385703614 cites W2086572083 @default.
• W2385703614 cites W2108216694 @default.
• W2385703614 cites W2116456562 @default.
• W2385703614 cites W2150231759 @default.
• W2385703614 cites W2171051792 @default.
• W2385703614 doi "https://doi.org/10.1186/s13195-016-0189-7" @default.
• W2385703614 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4866415" @default.
• W2385703614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27176461" @default.
• W2385703614 hasPublicationYear "2016" @default.
• W2385703614 type Work @default.
• W2385703614 sameAs 2385703614 @default.
• W2385703614 citedByCount "195" @default.
• W2385703614 countsByYear W23857036142016 @default.
• W2385703614 countsByYear W23857036142017 @default.
• W2385703614 countsByYear W23857036142018 @default.
• W2385703614 countsByYear W23857036142019 @default.
• W2385703614 countsByYear W23857036142020 @default.
• W2385703614 countsByYear W23857036142021 @default.
• W2385703614 countsByYear W23857036142022 @default.
• W2385703614 countsByYear W23857036142023 @default.
• W2385703614 crossrefType "journal-article" @default.
• W2385703614 hasAuthorship W2385703614A5009252002 @default.
• W2385703614 hasAuthorship W2385703614A5012191847 @default.
• W2385703614 hasAuthorship W2385703614A5016385021 @default.
• W2385703614 hasAuthorship W2385703614A5017541810 @default.
• W2385703614 hasAuthorship W2385703614A5020136275 @default.
• W2385703614 hasAuthorship W2385703614A5020866326 @default.
• W2385703614 hasAuthorship W2385703614A5025513316 @default.
• W2385703614 hasAuthorship W2385703614A5025870220 @default.
• W2385703614 hasAuthorship W2385703614A5033389610 @default.
• W2385703614 hasAuthorship W2385703614A5043338100 @default.
• W2385703614 hasAuthorship W2385703614A5049484291 @default.
• W2385703614 hasAuthorship W2385703614A5050897246 @default.
• W2385703614 hasAuthorship W2385703614A5052077345 @default.
• W2385703614 hasAuthorship W2385703614A5061039783 @default.
• W2385703614 hasAuthorship W2385703614A5071341444 @default.
• W2385703614 hasAuthorship W2385703614A5071619668 @default.
• W2385703614 hasAuthorship W2385703614A5076601074 @default.
• W2385703614 hasAuthorship W2385703614A5083343966 @default.
• W2385703614 hasAuthorship W2385703614A5086549440 @default.
• W2385703614 hasAuthorship W2385703614A5087508465 @default.
• W2385703614 hasAuthorship W2385703614A5087888043 @default.
• W2385703614 hasAuthorship W2385703614A5091783652 @default.
• W2385703614 hasBestOaLocation W23857036141 @default.
• W2385703614 hasConcept C126322002 @default.
• W2385703614 hasConcept C142724271 @default.
• W2385703614 hasConcept C143998085 @default.
• W2385703614 hasConcept C168563851 @default.
• W2385703614 hasConcept C185592680 @default.
• W2385703614 hasConcept C197934379 @default.
• W2385703614 hasConcept C203092338 @default.
• W2385703614 hasConcept C204787440 @default.
• W2385703614 hasConcept C27081682 @default.
• W2385703614 hasConcept C2779134260 @default.
• W2385703614 hasConcept C2779483572 @default.
• W2385703614 hasConcept C2781197716 @default.
• W2385703614 hasConcept C502032728 @default.
• W2385703614 hasConcept C535046627 @default.
• W2385703614 hasConcept C55493867 @default.
• W2385703614 hasConcept C71924100 @default.
• W2385703614 hasConceptScore W2385703614C126322002 @default.
• W2385703614 hasConceptScore W2385703614C142724271 @default.
• W2385703614 hasConceptScore W2385703614C143998085 @default.
• W2385703614 hasConceptScore W2385703614C168563851 @default.
• W2385703614 hasConceptScore W2385703614C185592680 @default.
• W2385703614 hasConceptScore W2385703614C197934379 @default.

• next